Platelet-activating Factor (PAF) Inhibitory Profile of KO-286011 on Blood Platelets in Vitro and in Vivo

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1990 Dec 1

PMID 2096302

Authors

G OSTERMANN

B Hofmann

H P Kertscher

U Till

Affiliations

Soon will be listed here.

Abstract

A newly synthesised structural analogue of PAF, coded KO-286011 (1-O-hexadecyl-2-O-ethyl-rac-glycero-3-phosphoric acid 4-(N,N-dimethylamino)pyridinium butylester), was proved for its ability to inhibit PAF-mediated platelet responses in vitro and in vivo. The compound inhibited effectively the PAF-induced aggregation and secretion of human and rabbit platelets. In contrast, there was little influence on ADP-, collagen-, and arachidonic acid-triggered platelet responses. Schild-analysis of aggregation data ascertained in human platelet-rich plasma was consistent with a simple competitive antagonism and yielded a pA2 of 6.44. Proaggregatory activity of KO-286011 was excluded turbidimetrically as well as by means of a single cell counting technique. [3H]PAF binding studies provided evidence that KO-286011 exerts its inhibitory action at the PAF-receptor level. A significant inhibition of the ex vivo PAF-induced platelet aggregation was found after i.v. administration of 0.5 mg/kg KO-286011 to rabbits. The effect was most pronounced 5 min after dosing the inhibitor and detectable over a period of 30 min. Intravenous administration of 10 and 25 micrograms/kg KO-286011 to guinea pigs prevented dose-dependently the PAF-induced formation of thromboxane A2. The PAF-inhibitory action of KO-286011 was more potent than that of the ginkgolide BN 52021.

References

Tokumura A, Homma H, HANAHAN D . Structural analogs of alkylacetylglycerophosphocholine inhibitory behavior on platelet activation. J Biol Chem. 1985; 260(23):12710-4. View

Hadvary P, Baumgartner H . Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. Thromb Res. 1983; 30(2):143-56. DOI: 10.1016/0049-3848(83)90237-2. View

Blank M, Lee T, Fitzgerald V, Snyder F . A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem. 1981; 256(1):175-8. View

Born G, Hume M . Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature. 1967; 215(5105):1027-9. DOI: 10.1038/2151027a0. View

Cox C . Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. Thromb Res. 1986; 41(2):211-22. DOI: 10.1016/0049-3848(86)90230-6. View

Dive G, Godfroid J, Lamotte-Brasseur J, Batt J, Heymans F, Dupont L . PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists. J Lipid Mediat. 1989; 1(4):201-15. View

Tokumura A, Yoshida J, Maruyama T, Fukuzawa K, Tsukatani H . Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. Thromb Res. 1987; 46(1):51-63. DOI: 10.1016/0049-3848(87)90206-4. View

OSTERMANN G, Kostner G, Gries A, Malle E, Till U . The contribution of individual lipoproteins to the degradation of platelet-activating factor in human serum. Haemostasis. 1989; 19(3):160-8. DOI: 10.1159/000215910. View

Handley D, Houlihan W, Tomesch J, Farley C, Deacon R, Koletar J . Chemistry and pharmacology of PAF antagonists. Evaluation of changes at potential metabolism sites on activity and duration of activity. Adv Prostaglandin Thromboxane Leukot Res. 1989; 19:367-70. View

10.

Hwang S, Lam M . Species difference in the specific receptors of platelet activating factor. Biochem Pharmacol. 1986; 35(24):4511-8. DOI: 10.1016/0006-2952(86)90772-0. View

11.

HANAHAN D . Platelet activating factor: a biologically active phosphoglyceride. Annu Rev Biochem. 1986; 55:483-509. DOI: 10.1146/annurev.bi.55.070186.002411. View

12.

Terashita Z, Tsushima S, Yoshioka Y, Nomura H, Inada Y, Nishikawa K . CV-3988 - a specific antagonist of platelet activating factor (PAF). Life Sci. 1983; 32(17):1975-82. DOI: 10.1016/0024-3205(83)90049-8. View

13.

OSTERMANN G, Hofmann B, Kertscher H, Till U . PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation. J Lipid Mediat. 1991; 3(2):225-37. View

14.

Joist J, Dolezel G, Cucuianu M, NISHIZAWA E, Mustard J . Inhibition and potentiation of platelet function by lysolecithin. Blood. 1977; 49(1):101-12. View

15.

Born G . Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962; 194:927-9. DOI: 10.1038/194927b0. View

16.

Demopoulos C, Pinckard R, HANAHAN D . Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979; 254(19):9355-8. View

17.

Fiedel B . Effects of lysolecithin on aggregation of human platelets induced by arachidonic acid and A23187 role of prostaglandin intermediary metabolism. Life Sci. 1978; 22(6):531-4. DOI: 10.1016/0024-3205(78)90435-6. View

18.

OSTERMANN G, Till U, THIELMANN K . Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. Thromb Res. 1983; 30(2):127-36. DOI: 10.1016/0049-3848(83)90235-9. View

19.

Arnout J, Van Hecken A, De Lepeleire I, Miyamoto Y, Holmes I, De Schepper P . Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. Br J Clin Pharmacol. 1988; 25(4):445-51. PMC: 1387806. DOI: 10.1111/j.1365-2125.1988.tb03328.x. View

20.

Handley D, Tomesch J, Saunders R . Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb Haemost. 1986; 56(1):40-4. View